Open Label Trial of Immunotherapy for Advanced Liver Cancer (HCC)
Open Label Trial of Hepcortespenlisimut-L (V5) Immunotherapy for HCC
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ulaanbaatar, Mongolia
- Immunitor LLC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who are at least 18 years old and are willing and capable of providing informed consent. Both men and non-pregnant women will be included.
- HCC diagnosis documented prior to Study Entry by either cytology/histology, CT scan, and AFP serum test higher or equal to 30 IU/ml.
- All subjects with reproductive potential are advised to utilize effective contraception throughout the course of this study.
- Health score status at baseline.
- Agreement to participate in the study and to give at least 3 samples of blood for lab tests.
- Readily available home or o other address where patient can be found.
Exclusion Criteria:
- Subjects who might have already taken V5 in prior trials and have no baseline data.
- Those who met inclusion criteria can be retrospectively enrolled.
- Pregnant or breast-feeding women are excluded.
- Subjects who have taken other immunomodulatory therapies within 2 months prior to Entry: systemic corticosteroids, immune globulin (IV gamma globulin, IVIG), interferons, interleukins, pentoxifylline (Trental), thalidomide, filgrastim (G-CSF), sargramostim (GM-CSF); dinitrochlorobenzene (DNCB), thymosin alpha 1 (thymosin alpha), thymopentin, inosiplex (Isoprinosine), polyribonucleoside (Ampligen), ditiocarb sodium (Imuthiol), any locally available immune modulators, and any other therapeutic or preventive HCC vaccine.
- Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry.
- Evidence of active or acute cardiac disease, epilepsy, or life-threatening diseases unrelated to HCC.
- Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator would interfere with adherence to the requirements of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Daily oral dose of hepcortespenlisimut-L
Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
|
Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of hepcortespenlisimut-L (V5) immunotherapy on serum levels of AFP (IU/ml) compared to baseline
Time Frame: minimum 3 months
|
monthly check-up of AFP serum levels
|
minimum 3 months
|
|
Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance
Time Frame: minimum 3 months
|
Comparison of abdominal CT scans at baseline and 3 months later
|
minimum 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of hepcortespenlisimut-L (V5) immunotherapy in patients with advanced HCC on blood biochemistry parameters
Time Frame: 3 months
|
Monthly blood biochemistry including liver function tests
|
3 months
|
|
Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance
Time Frame: 3 months
|
Monthly evaluation of clinical symptoms as per ECOG performance status
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Aldar Bourinbaiar, MD/PhD, Immunitor LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IMMV5 (Other Identifier: Immunitor LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Abstract of 75-patient Phase II study
Information identifier: PMCID: PMC4649454Information comments: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649454/pdf/2051-1426-3-S2-P200.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.